0001104659-22-010483.txt : 20220201
0001104659-22-010483.hdr.sgml : 20220201
20220201183426
ACCESSION NUMBER: 0001104659-22-010483
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220128
FILED AS OF DATE: 20220201
DATE AS OF CHANGE: 20220201
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Gelone Steven P.
CENTRAL INDEX KEY: 0001693064
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37558
FILM NUMBER: 22580660
MAIL ADDRESS:
STREET 1: 1000 CONTINENTAL DRIVE
STREET 2: SUITE 600
CITY: KING OF PRUSSIA
STATE: PA
ZIP: 19406
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Nabriva Therapeutics plc
CENTRAL INDEX KEY: 0001641640
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: L2
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 25-28 NORTH WALL QUAY
CITY: DUBLIN
STATE: L2
ZIP: D01 H104
BUSINESS PHONE: (610) 816-6640
MAIL ADDRESS:
STREET 1: 414 COMMERCE DRIVE
STREET 2: STE 120
CITY: FORT WASHINGTON
STATE: PA
ZIP: 19034
FORMER COMPANY:
FORMER CONFORMED NAME: Nabriva Therapeutics AG
DATE OF NAME CHANGE: 20150507
4
1
tm221371-6_4seq1.xml
OWNERSHIP DOCUMENT
X0306
4
2022-01-28
0
0001641640
Nabriva Therapeutics plc
NBRV
0001693064
Gelone Steven P.
414 COMMERCE DR.
SUITE 120
FORT WASHINGTON
PA
19034
1
1
0
0
President and COO
Share Options
0.45
2022-01-28
4
A
0
93400
0
A
2032-01-27
Ordinary Shares
93400
93400
D
Restricted Stock Units
2022-01-28
4
A
0
46700
0
A
Ordinary Shares
46700
46700
D
The option was granted on January 28, 2022, subject to shareholder approval; provided, that if such shareholder approval is not obtained, the option will remain outstanding and convert into a cash-settled share appreciation right.
Subject to the reporting person's continued employment with Nabriva Therapeutics plc (the "Issuer"), the option will vest over a four-year period beginning January 28, 2023. Twenty-five percent (25%) of the option will vest on the one (1) year anniversary of the date of grant, and the remaining seventy-five percent (75%) of the option will vest on a monthly pro-rata basis over the remaining vesting period.
The restricted stock units ("RSU") were granted on January 28, 2022, and each RSU represents a contingent right to receive one ordinary share of the Issuer subject to shareholder approval; provided, that if such shareholder approval is not obtained, then each RSU will represent the right to receive the economic equivalent of one ordinary share of the Issuer in cash on the applicable vesting date.
Subject to the reporting person's continued employment with the Issuer, the RSUs will vest in equal annual installments over four years with the first installment vesting on January 28, 2023.
/s/ J. Christopher Naftzger, by power of attorney
2022-02-01